Loading clinical trials...

COMPLETEDPHASE4

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

Clinical and Genetic Assessment of Treatment Response in Patients With Age-related Macular Degeneration Using Intravitreal Aflibercept Injection

NCT02689518•University of California, San Diego

View on ClinicalTrials.gov

Summary

Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)

Detailed Description

Clinical and genetic assessment of treatment response in patients with age-related macular degeneration using intravitreal aflibercept injection. This study seeks to determine if different genetic polymorphisms of vascular endothelial growth factor A (VEGF-A) and HtrA serine peptidase 1(HTRA1) and other genes correlate to the response to intravitreal aflibercept injection therapy.

Eligibility

Age

50 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥ 50 years
•2. Naïve neovascular wet-AMD (has not received treatment before)
•3. Willing and able to comply with clinic visits and study-related procedures
•4. Provide signed informed consent

Exclusion Criteria

•1. Previous therapy in study eye for AMD or other retinal disease which may be used in the treatment of AMD
•2. Previous subfoveal focal laser photocoagulation involving the foveal center in the study eye
•3. History of vitrectomy, submacular surgery, or other surgical intervention for AMD in the study eye
•4. Any concurrent intraocular condition in the study eye (e.g. diabetic retinopathy or glaucoma) that, in the opinion of the investigator, could either 4.1 require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition, or 4.2 if allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of best corrected visual acuity over the study period
•5. Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or autoimmune-associated uveitis in either eye
•6. Current vitreous hemorrhage in the study eye
•7. History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye
•8. Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
•9. Aphakia, ACIOL, or unstable PCIOL
•10. Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)
+3 more criteria

Locations (1)

Shiley Eye Center

La Jolla, California, United States

Key Dates

Start Date

April 1, 2014

Primary Completion Date

November 12, 2019

Completion Date

November 12, 2019

Last Updated

March 25, 2021

Enrollment

ACTUAL participants

Conditions

Macular DegenerationWet Macular Degeneration

Interventions

Intravitreal aflibercept injection

DRUG

Direct Discrimination of Quantum States by the Human Eye

NCT05913063

Age-Related Macular Degeneration

View study

RECRUITING

Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection

NCT07446582

Age-Related (Dry) Macular Degeneration

View study

RECRUITING

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

NCT06779773

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 25, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

Inclusion Criteria

Exclusion Criteria

Direct Discrimination of Quantum States by the Human Eye

Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration